ESUS in the Athens Stroke Registry George Ntaios University of Thessaly, Larissa/Greece Barcelona, 08 June 2016.

Slides:

Advertisements

Similar presentations

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.

Advertisements

CARDIOVASCULAR SYSTEM

Atrial fibrillation.

Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.

Κρυπτογενή εγκεφαλικά έμφρακτα:

Κρυπτογενές ισχαιμικό έμφρακτο Γεώργιος Ντάιος Επίκουρος Καθηγητής Παθολογίας, Πανεπιστήμιο Θεσσαλίας 3 ο Συνέδριο ΙΜΕΘΑ Αθήνα, 24/4/2014.

Embolic Stroke Emily Chang PGY-3 May 4, Definition Particles of debris that originate from another source that lead to blockage of arterial perfusion.

ESUS: Embolic Strokes of Undetermined Source

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,

Cerebral Vascular Disease

DR. HANA OMER CONGENITAL HEART DEFECTS. The major development of the fetal heart occurs between the fourth and seventh weeks of gestation, and most congenital.

Cardiovascular Disease in Women Module III: Risk Assessment Tool.

Transient Ischemic Attack (TIA): The Calm Before the Storm

Aetiology * MVP { Myxomatous mv },commonest in developed world *Damage to the cusps : _RVD _ IE _ Congenital Cleft MV *Damage to chordae : _RVD.

Stroke Awareness & Prevention Suheb Hasan, MD Health Seminar MCWS November 17, 2012.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Valvular Heart DISEASE

Secondary prevention after a TIA or ischemic stroke.

Mitral Valve Disease Prof JD Marx UFS January 2006.

Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.

Mechanisms that Produce a Stroke

University of Thessaly, Larissa, Greece

1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,

Cardio Investigations. Patients presenting with chest pain may be identified as having definite or possible angina from their history alone. Risk Factor.

10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.

UNEXPECTED CAUSE(S) OF CEREBRAL MICROEMBOLISATION INVESTIGATED BY TRANSCRANIAL DOPPLER DUPLEX COLOUR SONOGRAPHY Muriel SPRYNGER Cardiology-Angiology CHU.

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.

Cardiovascular disease in pregnancy Cardiovascular disease in pregnancy Dr.Z Allameh MD.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:

Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.

Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,

University of Thessaly, Larissa, Greece

Adult Cardiac Valve Disease Marvin D. Peyton, M.D. Thoracic and Cardiovascular Surgery University of Oklahoma Health Sciences Center.

What is a stroke? A stroke occurs when an artery supplying the brain either blocks or bursts.

CONGENITAL HEART DEFECTS DR. HANA OMER. CONGENITAL HEART DEFECTS D. HANA OMER.

Stroke in the era of NOACs George Ntaios MD, MSc (Stroke Medicine), PhD University of Thessaly, Greece Oslo 11/12/2015.

Dr. Meg-angela Christi M. Amores

Κρυπτογενή εγκεφαλικά έμφρακτα Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας.

KIDNEY & HYPERTENTION 1 Dr. Ruba Nashawati. Kidney Hypertension 2.

Cardioembolic Stroke: Diagnosis and Management

Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung.

Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.

Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,

Embolic Strokes of Undetermined Source

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for the management of patients.

Ischaemic heart disease. Coronary artery disease(CAD) is the leading cause of death worldwide. The rates of mortality and disability due to CAD are increasing.

CARDIOEMBOLIC STROKE Debasis Das, MD, FACC Interventional Cardiologist CHI St. Vincent Heart Clinic Arkansas April 25, 2015.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate.

Initiating prevention after acute stroke in NVAF and beyond George Ntaios University of Thessaly, Larissa/Greece.

Cryptogenic Stroke and AF

Heart - Pathophysiology

Investigations of the Cardiovascular system

Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,

2 A Cardiology Department, University of Athens

Copyright © 2007 American Medical Association. All rights reserved.

Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.

Congenital Diseases Dr. Gerrard Uy.

Novel oral anticoagulants in comparison with warfarin

Atrial fibrillation (AF) and flutter

Setareh Omran, MD Vascular Neurology Fellow

ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA

A. Epidemiology update:

Fibrillazione atriale

Volume 14, Issue 9, Pages (September 2015)

Figure 2 Echocardiographic methods to estimate left atrial pressure

The Cardiovascular Health Study:

Cardiovascular Disease in Women Module III: Risk Assessment Tool

Presentation transcript:

ESUS in the Athens Stroke Registry George Ntaios University of Thessaly, Larissa/Greece Barcelona, 08 June 2016

The Athens Stroke Registry, by K. Vemmos

ESUS in the Athens Stroke Registry

Patients with acute first-ever ischaemic stroke (n= 2,735 ) ESUS (n= 275 ) n=2,731 n=2,109 n=1,612 n=743 n=641 Patients with missing data (n=4) Patients with lacunar stroke detected by CT or MRI (n=622) Presence of extracranial or intracranial atherosclerosis causing ≥50% luminal stenosis in arteries supplying the area of ischaemia (n=497) Major-risk cardioembolic source of embolism (n=869) Other/rare specific causes (n=102) Incomplete diagnostic work-up (or ≥2 causes identified) or non-visualised infarct (n=366)

ESUS in the Athens Stroke Registry: Patient characteristics ESUS (n=275) Large-artery atherosclerotic (n=497) Cardioembolic (n=869) Lacunar (n=622) Undetermined other than ESUS (n=366) Other determined (n=102) Demographics Female sex, n (%)99 (36.0)114 (22.9)461 (53.0)173 (27.8)166 (45.4)49 (48.0) Median (IQR) age, years68.0 (58.0–76.0)67.0 (60.0–73.0)76.0 (70.0–82.0)69.0 (60.0–75.0)74.0 (67.0–81.0)56.0 (43–74) Comorbidities – risk factors, n (%) Hypertension178 (64.7)382 (76.9)631 (72.6)518 (83.3)259 (70.8)50 (49.0) Diabetes mellitus65 (23.6)163 (32.8)192 (22.1)181 (29.1)115 (31.4)17 (16.7) Smoking83 (30.2)251 (50.5)157 (18.1)235 (37.8)111 (30.3)39 (38.2) Previous TIA27 (9.8)102 (20.5)53 (6.1)59 (9.5)39 (10.7)17 (16.7) Heart failure22 (8.0)23 (4.6)139 (16.0)15 (2.4)31 (8.5)10 (9.8) Dyslipidemia140 (50.9)273 (55.3)266 (30.7)306 (49.4)159 (43.6)40 (39.2) Coronary artery disease65 (23.7)132 (26.8)169 (19.5)84 (13.6)86 (23.7)16 (15.7) AF0 (0.0)21 (4.2)774 (89.1)36 (5.8)41 (11.2)0 (0.0) Mode of onset, n (%) Maximal at onset204 (74.2)255 (51.3)713 (82.1)290 (46.6)219 (59.8)58 (56.9) Gradual worsening37 (13.5)112 (22.5)82 (9.4)99 (16.0)62 (16.9)15 (14.7) Shuttering/stepwise15 (5.5)66 (13.3)24 (2.8)132 (21.3)25 (6.8)9 (8.8) Flactuating4 (1.5)23 (4.6)10 (1.2)40 (6.5)11 (3.0)8 (7.8) Unknown or missing data15 (5.5)41 (8.2)39 (4.5)59 (9.5)49 (13.4)12 (11.8)

ESUS in the Athens Stroke Registry: Patient characteristics ESUS (n=275) Large-artery atherosclerotic (n=497) Cardioembolic (n=869) Lacunar (n=622) Undetermined other than ESUS (n=366) Other determined (n=102) Demographics Female sex, n (%)99 (36.0)114 (22.9)461 (53.0)173 (27.8)166 (45.4)49 (48.0) Median (IQR) age, years68.0 (58.0–76.0)67.0 (60.0–73.0)76.0 (70.0–82.0)69.0 (60.0–75.0)74.0 (67.0–81.0) 56.0 (43.0– 74.0) Comorbidities – risk factors, n (%) Hypertension178 (64.7)382 (76.9)631 (72.6)518 (83.3)259 (70.8)50 (49.0) Diabetes mellitus65 (23.6)163 (32.8)192 (22.1)181 (29.1)115 (31.4)17 (16.7) Smoking83 (30.2)251 (50.5)157 (18.1)235 (37.8)111 (30.3)39 (38.2) Previous TIA27 (9.8)102 (20.5)53 (6.1)59 (9.5)39 (10.7)17 (16.7) Heart failure22 (8.0)23 (4.6)139 (16.0)15 (2.4)31 (8.5)10 (9.8) Dyslipidemia140 (50.9)273 (55.3)266 (30.7)306 (49.4)159 (43.6)40 (39.2) Coronary artery disease65 (23.7)132 (26.8)169 (19.5)84 (13.6)86 (23.7)16 (15.7) AF0 (0.0)21 (4.2)774 (89.1)36 (5.8)41 (11.2)0 (0.0) Mode of onset, n (%) Maximal at onset204 (74.2)255 (51.3)713 (82.1)290 (46.6)219 (59.8)58 (56.9) Gradual worsening37 (13.5)112 (22.5)82 (9.4)99 (16.0)62 (16.9)15 (14.7) Shuttering/stepwise15 (5.5)66 (13.3)24 (2.8)132 (21.3)25 (6.8)9 (8.8) Flactuating4 (1.5)23 (4.6)10 (1.2)40 (6.5)11 (3.0)8 (7.8) Unknown or missing data15 (5.5)41 (8.2)39 (4.5)59 (9.5)49 (13.4)12 (11.8)

ESUS in the Athens Stroke Registry: Patient characteristics ESUS (n=275) Large-artery atherosclerotic (n=497) Cardioembolic (n=869) Lacunar (n=622) Undetermined other than ESUS (n=366) Other determined (n=102) Demographics Female sex, n (%)99 (36.0)114 (22.9)461 (53.0)173 (27.8)166 (45.4)49 (48.0) Median (IQR) age, years68.0 (58.0–76.0)67.0 (60.0–73.0)76.0 (70.0–82.0)69.0 (60.0–75.0)74.0 (67.0–81.0) 56.0 (43.0– 74.0) Comorbidities – risk factors, n (%) Hypertension178 (64.7)382 (76.9)631 (72.6)518 (83.3)259 (70.8)50 (49.0) Diabetes mellitus65 (23.6)163 (32.8)192 (22.1)181 (29.1)115 (31.4)17 (16.7) Smoking83 (30.2)251 (50.5)157 (18.1)235 (37.8)111 (30.3)39 (38.2) Previous TIA27 (9.8)102 (20.5)53 (6.1)59 (9.5)39 (10.7)17 (16.7) Heart failure22 (8.0)23 (4.6)139 (16.0)15 (2.4)31 (8.5)10 (9.8) Dyslipidemia140 (50.9)273 (55.3)266 (30.7)306 (49.4)159 (43.6)40 (39.2) Coronary artery disease65 (23.7)132 (26.8)169 (19.5)84 (13.6)86 (23.7)16 (15.7) AF0 (0.0)21 (4.2)774 (89.1)36 (5.8)41 (11.2)0 (0.0) Mode of onset, n (%) Maximal at onset204 (74.2)255 (51.3)713 (82.1)290 (46.6)219 (59.8)58 (56.9) Gradual worsening37 (13.5)112 (22.5)82 (9.4)99 (16.0)62 (16.9)15 (14.7) Shuttering/stepwise15 (5.5)66 (13.3)24 (2.8)132 (21.3)25 (6.8)9 (8.8) Flactuating4 (1.5)23 (4.6)10 (1.2)40 (6.5)11 (3.0)8 (7.8) Unknown or missing data15 (5.5)41 (8.2)39 (4.5)59 (9.5)49 (13.4)12 (11.8)

ESUS (n=275) Large-artery atherosclerotic (n=497) Cardioembolic (n=869) Lacunar (n=622) Undetermined other than ESUS (n=366) Other determined (n=102) Clinical and laboratory values Systolic blood pressure, mm Hg 150 (130– 160) 150 (140–170)150 (130–170) 160 (140– 180) 150 (135–170) 140 (120– 150) Diastolic blood pressure, mm Hg 85 (80–90)90 (80–90)85 (80–90) 90 (80– 100) 84 (80–90)80 (70–90) Glucose, mg/dL 109 (93– 141) 111 (95–154)118 (98–153) 105 (92– 139) 116 (98–163) 100 (90– 125) NIHSS score5 (2–14)5 (2–15)13 (4–22)2 (1–4)8 (3–18)4 (1–12) ESUS in the Athens Stroke Registry: Stroke severity

ESUS: Potential causes Mitral valve Myxomatous valvulopathy with prolapse 5 (1.8%) Mitral annular calcification 8 (2.9%) Aortic valve Aortic valve stenosis 3 (1.1%) Calcific aortic valve 12 (4.4%) Non-AF atrial dysrhythmias and stasis Atrial asystole and sick-sinus syndrome 3 (1.1%) Atrial high-rate episodes 7 (2.6%) Atrial appendage stasis with reduced flow velocities or spontaneous echodensities 6 (2.2%) Atrial structural abnormalities Atrial septal aneurysm 10 (3.6%) Chiari network 0 (0.0%) Left ventricle Moderate systolic or diastolic dysfunction 42 (15.4%) Ventricular non-compaction 12 (4.4%) Endomyocardial fibrosis 1 (0.4%) Covert paroxysmal AF (detected during follow-up) AF detected on stroke recurrence 30 (11.0%) AF detected on monitoring during follow-up 50 (18.3%) AF not confirmed but strongly suspected 38 (13.9%) Cancer associated Covert non-bacterial thrombotic endocarditis 1 (0.4%) Tumour emboli from occult cancer 2 (0.8%) Arteriogenic emboli Aortic arch atherosclerotic plaques 9 (3.3%) Cerebral artery non-stenotic plaques with ulceration 29 (10.6%) Paradoxical embolism Patent foramen ovale 11 (4.0%) Atrial septal defect 3 (1.1%)

AF ESUS (n=80) Non-AF ESUS (n=195) p-value NIHSS score5 (2–13)5 (2–14)0.998 J Stroke Cerebrovasc Dis. in revision ESUS & AF at follow-up: How much causality is there?

ESUS outcome ~ 9% lost to follow-up Mean follow-up was 38.7 months Total follow-up was 10,642 patient-years

ESUS: 5-year functional outcome mRS = 0-1 mRS = >1 ESUS Cardioembolic Large-artery atherosclerotic Lacunar Undetermined other than ESUS Miscellaneous

ESUS: 5-year stroke recurrence 0 ESUS Risk of stroke recurrence (%) Months Cardioembolic Large-artery atherosclerotic Undetermined other than ESUS Lacunar Miscellaneous

ESUS: 5-year stroke recurrence

ESUS: 5-year stroke outcomes

ESUS: 5-year cardiovascular events

ESUS: 5-year mortality

Risk stratification for recurrence & mortality Stroke, in revision

Take-home messages ~10% of all stroke patients Mild strokes in relatively younger patients ESUS look more like atherosclerotic rather than AF patients Covert AF is frequently detected in ESUS Perhaps AF is over-estimated as a stroke cause (at least in ESUS…) High recurrence rate Supports that NAVIGATE is indeed an ESUS trial.

Back-up slides – etiologic work-up Etiologic work-up Continuous ECG monitoring in the stroke unit 195 (70.9%)276 (55.5%)564 (64.9%)289 (46.5%)187 (51.1%)55 (53.9%) 24-hours Ambulatory Holter Monitoring 142 (51.6%)26 (5.2%)56 (6.4%)17 (2.7%)40 (10.9%)24 (23.5%) No rhythm monitoring modality other than admission ECG 0 (0.0%)206 (41.4%)296 (34.1%)322 (51.8%)156 (42.6%)30 (29.4%) Transthoracic echocardiography 247 (89.8%)221 (44.5%)365 (42.0%)277 (44.5%)123 (33.6%)67 (65.7%) Transesophageal echocardiography 83 (30.2%)22 (4.4%)83 (9.6%)20 (3.2%)16 (4.4%)12 (11.8%) Any angiography (CT or MR or digital) ** 239 (86.9%)323 (65.0%)53 (6.1%)150 (24.1%)33 (9.0%)50 (49.0%) Cervical artery ultrasound 252 (91.6%)465 (93.6%)376 (43.3%)516 (83.0%)177 (48.4%)80 (78.4%) No cervical artery imaging 0 (0.0%) 481 (55.4%)92 (14.8%)186 (50.8%)15 (14.7%)